drugset / Trial / NCT03840993

Safety and Efficacy Study of MT-2990 in Women With Endometriosis

NCT03840993 ↗

Phase 2 Completed 76 enrolled Tanabe Pharma America, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the safety and efficacy of MT-2990 for treatment of moderate to severe endometriosis-related pain in women with surgically diagnosed endometriosis.

Timeline

Start
2019-01-15
Primary completion
2021-05-13
Completion
2021-10-05

Drugs

EvaluationDrugModalityDoseRoute
Subject MT-2990 Unknown — —

Indications